The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer
Clinical and Translational Oncology · 13.03.2026 · 28 (9) · 3754-3773
DOI: 10.1007/s12094-026-04249-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 13.03.2026. Verfasst von Yanyan Hao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical U…. Hauptthemen laut MEDLINE: Autoantibodies, Lung Neoplasms, Biomarkers, Tumor, Early Detection of Cancer. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To investigate the diagnostic value of seven lung cancer-related autoantibodies (7-AABs) and four tumor markers (4-TMs) for the early detection of lung cancer, aiming to assess their combined effectiveness compared to individual applications. METHODS: We analyzed serum samples from 110 lung cancer patients and 50 age-matched patients with benign lung nodules. Serum concentrations of 7-AABs (including SOX2, GAGE 7, CAGE, MAGE A1, P53, GBU4-5, and PGP9.5) and 4-TMs (CEA, NSE, CYFRA21‑1, and SCCA) were measured using ELISA. Receiver operating characteristic (ROC) curves were conducted to evaluate the value of combining tumor markers with serum 7-AABs for early diagnosis of lung cancer. RESULTS: In the malignant group, significantly elevated levels of seven autoantibodies (7-AABs), including SOX2, GAGE 7, CAGE, MAGE A1, P53, GBU4-5, and PGP9.5, as well as four tumor markers (4-TMs), namely CEA, NSE, CYFRA21‑1, and SCCA, were observed compared to the benign group, with markedly higher positivity rates for these biomarkers in the malignant group. The combined analysis of 7-AABs and 4-TMs yielded the highest diagnostic accuracy with an AUC of 0.977, significantly improving sensitivity and specificity. Notably, SOX2 and CEA showed distinct patterns across different lung cancer histological types, enhancing diagnostic differentiation. Furthermore, decision curve analysis (DCA) demonstrated the superior clinical net benefit of the 7-AABs full model over a baseline P53 model across a wide range of risk thresholds, providing a more clinically relevant metric for evaluating diagnostic performance. CONCLUSION: Our findings suggest that combining autoantibodies and tumor markers may improve the early detection of lung cancer, offering a potentially non-invasive, cost-effective, and accurate diagnostic tool. However, due to the limitations of our study, such as the relatively small sample size and single-center design, these results need to be validated in larger, multi-center cohorts. This combined biomarker approach could complement existing screening methods, but further research is required to confirm its clinical utility and integration into current screening practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, No.99, Longcheng Street, Xiaodian D…
Zitieren
APA
Hao, Y., Wang, P., Zhao, Z., & Cheng, J. (2026). The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer. Clinical and Translational Oncology, 28(9), 3754-3773. https://doi.org/10.1007/s12094-026-04249-0
Vancouver
Hao Y, Wang P, Zhao Z, Cheng J. The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer. Clinical and Translational Oncology. 2026;28(9):3754-3773. doi:10.1007/s12094-026-04249-0
BibTeX
@article{Hao2026,
author = {Hao, Yanyan and Wang, Pengfei and Zhao, Zhiping and Cheng, Jiande},
title = {The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer},
journal = {Clinical and Translational Oncology},
year = {2026},
volume = {28},
number = {9},
pages = {3754--3773},
doi = {10.1007/s12094-026-04249-0}
}
EUVIMED